logo.jpg
Biofrontera provides clinical development updates
February 19, 2020 05:45 ET | Biofrontera AG
Leverkusen, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
logo.jpg
European Medicines Agency recommends indication expansion of Ameluz® for treatment of actinic keratoses on the extremities and trunk/neck
February 03, 2020 05:45 ET | Biofrontera AG
Leverkusen, Germany, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...
logo.jpg
Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter
January 10, 2020 05:00 ET | Biofrontera AG
Leverkusen, Germany, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its...
Logo_Biofrontera_AG.png
Biofrontera strengthens commercial focus with reorganization of its US business
January 06, 2020 09:00 ET | Biofrontera AG
Leverkusen, Germany, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced a new...
logo color s and clearside.jpg
Clearside Biomedical to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Logo_Biofrontera_AG.png
Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.
December 13, 2019 08:20 ET | Biofrontera AG
Leverkusen, Germany, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...
Logo_Biofrontera_AG.png
Biofrontera to Participate in Upcoming Investor Conferences
November 22, 2019 11:06 ET | Biofrontera AG
Leverkusen, Germany, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its...
Logo_Biofrontera_AG.png
Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
October 10, 2019 05:15 ET | Biofrontera AG
Leverkusen, Germany, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceutical...
Logo_Biofrontera_AG.png
Biofrontera to present at the Baader Investment Conference
September 17, 2019 09:45 ET | Biofrontera AG
Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced that Prof....
Logo_Biofrontera_AG.png
Results of the voluntary partial tender offers
July 24, 2019 06:30 ET | Biofrontera AG
Leverkusen, Germany, July 24, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the...